The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
9
5mg, i.v. single dose
Novartis Investigative Site
Beijing, China
Novartis Investigative site
Guangzhou, China
Novartis Investigative site
Nanjing, China
Novartis Investigative site
Shanghai, China
The proportion of patients who achieve therapeutic response (a reduction of at least 75% from baseline in total Serum Alkaline Phosphatase (SAP) excess or normalization of SAP.
Time frame: at the end of 3 months and 6 months
The percent change from baseline in total Serum Alkaline Phosphatase (SAP).
Time frame: at the end of 3 months and 6 months
The percent change from baseline in serum cross-linked C-telopeptide of type I collagen (CTX).
Time frame: at the end of 3 months and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.